Drug Discovery World
 

Home | Industry News Archive |

First Minister To Open BioWales 2010

Feb 2010

 First Minister of Wales Carwyn Jones will open this year’s BioWales, the eighth annual bioscience event at the Vale of Glamorgan Hotel on March 17, just months after being elected leader of the Welsh Assembly Government. more...

AAIPharma Services Announces New Additions

Feb 2010

 AAIPharma Services Corporation announced today the addition of Inductively Coupled Plasma Mass Spectrometry (ICP-MS) to its full line of mass spectrometry capabilities. “This new capability along with our commitment to technological advancement and our rich history of scientific excellence will provide our customers with a tremendous platform to support their drug product development efforts," said L. Lee Karras, CEO. more...

Flexion Makes Agreements With Major Companies

Feb 2010

 Flexion Therapeutics today announced agreements with four major pharmaceutical partners, acquiring the rights to four clinical-stage compounds, and gaining investment from the world’s biggest pharmaceutical company.The agreements with AstraZeneca, Merck Serono (a division of Merck KGaA, Darmstadt, Germany) and one other partner establish for Flexion a mature pipeline of clinically enabled drug candidates focused on inflammatory diseases. more...

Proximagen Issues Strategic Update

Feb 2010

 Since the £50m fundraising in June 2009, the Company has seen a period of unprecedented corporate activity and undergone a notable transition. During this time, the Company has evolved from specialising mainly in Parkinson’s disease related programmes to the wider area of the CNS in general. The purpose of this announcement is to update shareholders on the progress made since June 2009. more...

Synosia Announces Positive Interim Results

Feb 2010

 Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease. The Phase IIa trial was a randomised, double-blind, placebo-controlled, cross-over study in 24 Parkinson’s patients using doses up to 120mg/day for one week. more...

Daiichi Sankyo Submits New Drug Application

Feb 2010

 Daiichi Sankyo Company, Limited (hereafter; Daiichi Sankyo), today announced that it has submitted a New Drug Application to the Ministry of Health, Labor and Welfare for approval in Japan of CS-8958, a proprietary anti-flu drug. CS-8958 is a laninamivir prodrug that is a Long-Acting Neuraminidase Inhibitor. more...

Peakdale Announce Research Collaboration

Feb 2010

 Peakdale Molecular Limited (“Peakdale”), a leading research Services Company headquartered in the UK, announced today that it has entered into an agreement with Pfizer Limited. Peakdale Molecular, through its wholly-owned subsidiary Peakdale Chemistry Services Ltd, will supply custom synthetic chemistry services to Pfizer onsite at the company’s laboratories in Sandwich, UK. more...

Syrris establishes Brazilian subsidiary

Feb 2010

 Leading chemistry automation product innovator, Syrris established its new Brazilian subsidiary at the beginning of January 2010. With offices on four continents and an expanding distributor network, the new office in São Paulo will enable Syrris to provide efficient and direct support to its rapidly expanding Latin American customer base. more...

MorphoSys Licenses Antibody Library to Shionogi

Jan 2010

 MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Shionogi & Co., Ltd., Osaka, Japan, has elected to expand its current research license to cover the use of MorphoSys's HuCAL PLATINUM technology in drug discovery.

more...

Alizé Pharma Signs Collaboration With Lilly

Jan 2010

 Alizé Pharma, a group of companies developing innovative therapeutics for metabolic diseases and cancer, announced today that Alizé Pharma SAS has entered into a research collaboration and license option agreement with Eli Lilly and Company (NYSE:LLY) regarding Alizé Pharma's AZP-01 program, a program focused on the development of unacylated ghrelin (UAG) agonists for the treatment of type II diabetes. more...

Pharma Funds Cantab Biopharmaceuticals

Jan 2010

 Celtic Pharma Holdings Advisors LLP (“CPHA”), today announces it has made significant funding available to Cantab Biopharmaceuticals Limited (“Cantab”) for the development of improved biological medicines or ‘biosuperiors’, via the fund Celtic Pharma Holdings II LP (“CP2”). more...

First Patient Dosed in Hemophilia B Trial

Jan 2010

 Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: BVT) today announced that the first patient was dosed in a registrational, open-label, multicenter trial designed to evaluate the safety, pharmacokinetics and efficacy of the companies' long-acting, recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. more...

Cyntellect Expands Network Across Asia

Jan 2010

 Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, today announces availability of the full Cyntellect product portfolio, including the Celigo™ Adherent Cell Cytometer, the LEAP™ Cell Processing Workstation, and related kits and consumables, to the rapidly expanding life science sector in Asia. more...

More Links:

SEARCH

Advanced